My PCP Will Not Prescribe GLP-1: Why Not Go Compounded?

Your insurance premium buys you a primary care physician, and your PCP will not prescribe GLP-1 medication. So you did the sensible thing with what you were offered and found an app that would. The app routes your refills through a telehealth clinician you met once, on a short video call, who signs them. Three parties now hold a piece of your care. Each one bills you, and none of them has seen what the other two know.

A few months in, a fair question forms. If nobody is really managing this, why pay for the branded version at all? A compounded version is cheaper, the app or one of its competitors will supply it, and the oversight would be just as thin either way. This piece answers that question for your situation in particular: the three bills, the gap between them, and what a cheaper vial does and does not change. We have a stake in the answer, because GoodLife Health prescribes branded medication only, so weigh what follows with that in mind.

Three bills, and nobody holding the whole chart

In practice the arrangement tends to run like this. Your primary care physician sees you for a short visit, orders whatever the plan covers, and tells you that weight medication is something to discuss with whoever prescribes it. The app has your starting weight, the dose you are on, and a check-in form you fill out each month. The signer has a questionnaire and a refill queue. Your lab results, if anyone has drawn them since you started, sit in the PCP's portal, where neither the app nor the signer looks.

For a while this works well enough. The medication does something, the boxes arrive, the refills go through. Then one of two things happens, and often both. The scale stops moving at a high dose, or a side effect shows up that does not settle and that nobody seems to own. You message the app, and it suggests you speak with your doctor. Your doctor suggests you speak with the prescriber. The signer approves the next refill. Then the email arrives, on schedule, proposing the next step up in dose.

None of the three is doing anything wrong by its own lights. Each was built for a narrow job. The PCP is paid for visits billed to your plan, and those visits are short, the kind of eight-minute visit with room for one question. The app is paid to keep the prescription running. The signer is paid to review and sign. Nobody in the arrangement is paid to sit with the whole picture and ask why the medication stopped working, so nobody does.

That is why the compounded question feels reasonable. If the care around the drug is going to be thin regardless, the drug looks like the only line on the bill you can control. You have been sent from one office to the next and back again, and you are now asking a sensible question about money. The rest of this piece takes it seriously, starting with the part most people are told least clearly.

What is actually going on: two problems that look like one

The bill you can see and the care you are missing are separate problems, and compounding speaks to only one of them. Start with the one it speaks to.

Compounded GLP-1 existed at scale because of a shortage. When a medicine is on the FDA's drug shortage list, federal law lets pharmacies make copies of it to fill the gap. Semaglutide and tirzepatide went on that list in 2022, and for roughly three years many telehealth companies sold compounded copies. Millions of people used them, legally, and did nothing wrong. Then supply caught up. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved on February 21, 2025. The last enforcement grace periods for compounding pharmacies closed in spring 2025. The compounding industry's trade group sued to stop the shortage determinations, federal courts declined to block them, and both manufacturers have sued companies selling compounded versions. In 2026 the FDA proposed permanently excluding both medicines from the list that outsourcing facilities may compound in bulk.

What remains is narrow. A pharmacy may still compound a medicine for one specific patient with a documented clinical need the branded product cannot meet, such as an allergy to an ingredient. Some companies continue on that basis. The FDA has published its concerns about unapproved GLP-1 drugs used for weight loss, including reports about dosing and about ingredients added to some compounded versions. We will not tell you that compounded medication is dangerous in itself. We do not know your pharmacy, and whether a given company's use of the exception is appropriate is a legal and clinical question we cannot answer from here. What we can say is that a compounded GLP-1 in late 2026 rests on an exception rather than a rule, and the clinician who signs for it carries that responsibility on their license. In your arrangement, that clinician is the one you met once.

The branded side has moved too. In September 2026 the manufacturers published their own self-pay prices. Through NovoCare, Wegovy pens cost $199 a month for the first two fills, an introductory offer for new patients through December 2026, and $349 a month after that; the Wegovy pill starts at $149 a month at lower doses. Through LillyDirect, Zepbound vials cost $299 to $449 a month depending on dose. The branded medicines are the ones tested in the large published trials, made by the companies that ran them. Prices change, so check those pages yourself before you compare anything. We will not quote a compounded price, because we do not have a current one we can stand behind.

Now the problem compounding does not touch. The way your app gets paid shapes what it does, and our whitepaper on how GLP-1 telehealth companies make money describes the three models in plain language: a margin on the medicine, a low membership fee plus billing your insurance, or one flat fee with the medicine sold at the pharmacy's own price. In the first model the membership looks small and the profit sits in the medication, which quietly rewards more prescribing and faster escalation. We do not know which model your app runs, and it may run more than one; its pricing page usually tells you. Either way, an escalation email that arrives on a calendar makes more sense once you can see who benefits when the dose goes up.

A plateau at a high dose, or a side effect nobody owns, is a clinical question. The question is why, and answering it takes a lab panel, a clinician who reads it, and the same clinician reading the next one a quarter later. Switching to a compounded version changes what you pay the pharmacy. It leaves the clinical question exactly where it was, in the gap between three providers, and adds one more uncertainty about what is in the vial and on what legal basis it was made.

What GoodLife Health does about it, what it costs, and what it does not do

GoodLife Health is clinician-led, precision direct primary care for Cardiometabolic Optimization. In practice that means one clinical home that does, in order, what your three providers each do in part: diagnosis first, then treatment, then the long haul.

It starts with testing. The membership includes four cardiometabolic lab panels a year, one every quarter, and every result goes into your hands. A clinician reads the first panel with you before any decision about medication, then reads the next one against it, so your markers are followed over time instead of drawn once and filed. When something changes between panels, there is somewhere for it to go: asynchronous messaging with the care team, and video visits when a conversation is needed. Clinicians are licensed in all fifty states.

When medication is clinically indicated, it is branded and FDA-approved: Wegovy, Zepbound, Mounjaro or Ozempic for GLP-1, prescribed to the pharmacy you choose at that pharmacy's own price. GoodLife Health sets nothing, sees nothing and takes nothing on medication. The membership fee is the same whatever medication is indicated and whatever the dose, with no molecule upcharge and no dose upcharge, so nothing in the business gains when your dose goes up. That is our answer to the objection that the drug is the expensive part. The drug is often the larger cost, and it sits between you and your pharmacy, at the prices the manufacturers and pharmacies publish. The membership pays for the part you do not currently have. Our guide to Aligned Medicine and zero-markup care shows how that separation works, including the point that Zepbound and Mounjaro are the same molecule.

We do not prescribe compounded GLP-1, at any price. That is a choice, and it has a cost you should see clearly: members pay the branded price, which is higher. We made it because we want our clinicians prescribing the FDA-approved product at a published price, with nothing taken on it, and because the shortage that made compounding necessary ended in 2025.

Your insurance stays. The membership pairs with insurance for catastrophic coverage, meaning the hospital and the emergency you hope never comes, and it replaces the primary-care relationship. Whether a medication is covered by your plan is between you, the plan and the pharmacy. Prior authorization is the pharmacy's process, and GoodLife Health never claims to run it, speed it or win it. The membership fee is generally eligible for HSA or FSA pre-tax dollars.

Not everyone is accepted. The path is the eligibility check, an intake, the checkout, and then a clinician's review. We promise no particular weight loss, no remission and no coverage. What we commit to is the testing, the reading of it, and a clinician who stays.

The price is $299 a month. At sign-up, $598 is charged and covers the first two months; after that the membership runs month to month. If the clinician cannot accept you into care, the $598 is refunded in full. Once you are accepted, the first two months are non-refundable. Medication billed by a pharmacy follows that pharmacy's own return and refund policy. Over a full year, the membership is $3,588.

So, why not compounded? The honest answer, and what to do this week

If the monthly price of the medication were your only problem, compounding would be a question about pharmacies, regulators and your own tolerance for uncertainty, and the manufacturers' self-pay pages would be the place to start the comparison. For a patient paying three providers, price is the smaller problem. The larger one is that nobody is asking why the medication stopped working, nobody owns the side effect, and the next dose increase is being proposed by the party with the least information about you. A cheaper version of the same medication, signed by the same clinician you met once, leaves all of that in place.

The field has moved on dates you can check. Mass compounding ended with the grace periods in spring 2025. The manufacturers now publish self-pay prices for branded medication, dated September 2026 at the time of writing. Membership care, with one flat fee for the clinical relationship and the medicine sold at the pharmacy's own price, is the third payment model our whitepaper sets out beside the other two. None of that requires you to join anything this week. These four steps are worth doing either way.

1. Ask your app, in writing, whether your medication is branded or compounded, which pharmacy fills it, and, if it is compounded, on what basis now that both shortages have been declared resolved.
2. Ask each of your three providers for your most recent lab results and the date they were drawn, and put them in one place. If nothing has been drawn since you started the medication, write that down too.
3. Look up the current self-pay price for your medication on the manufacturer's own page, so any comparison with compounded uses this month's numbers instead of last year's.
4. Write a short history: every dose, the date of each change, and every side effect with when it started. Whoever you see next, including your own PCP, then starts from the whole picture instead of a form.

Who this is not for

This is not for you if the price of the medication is the whole decision and you would take the lowest-priced option however it is made. GoodLife Health is more expensive than most memberships, it does not prescribe compounded GLP-1, and a $99-a-month compounded app will serve that goal better than we will. GoodLife Health sits between the $20,000-a-year concierge practice and that app, and we would rather say so now than after checkout. It is not for you if your PCP turns out to be willing to prescribe and to draw labs on a schedule; one engaged clinician inside your insurance may be all you need. It is not for you if you want a prescription without a lab panel or a clinician's review, if you are looking for something to replace your insurance, or if you live outside the fifty states. And it is not for you if you want a promise about how much weight you will lose or whether your plan will cover a drug, because nobody honest can make one.

If you are the reader this was written for, here is the offer in plain terms. GoodLife Health costs $299 a month, with $598 charged at sign-up for the first two months and month to month after that; if the clinician cannot accept you into care, the $598 is refunded in full, and once you are accepted the first two months are non-refundable. It buys the quarterly panel, a clinician who stays and reads every result with you, and medication, when indicated, prescribed to your pharmacy at that pharmacy's price, with nothing taken on it. It returns what your three providers have not produced between them: an answer to why the medication stopped working, your markers followed over time, and an end to the eight-minute visit that closes with "ask your prescriber." It is different because it tests first and treats second, and it sells neither the drug nor the dose. The reason to start now is in your inbox: the next escalation email is coming, and the first panel should be read before you answer it.

Related Reading

• How GLP-1 Telehealth Companies Make Money: A Plain-Language Whitepaper
• Aligned Medicine: How Zero-Markup Healthcare Actually Works

References

1. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
2. NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
3. Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings